AbbVie's Rinvoq Bolsters Its Potential In Atopic Dermatitis

JAK1 Inhibitor ‘Clears’ Second Of Three Phase III AD Trials

AbbVie's Rinvoq has performed well in the second of three Phase III studies evaluating its potential treatment for atopic dermatitis, further boosting chances the JAK1 inhibitor will become a blockbuster in that indication.

Steps
Late Stage Measure Up 2 study was second of three assessing Rinvoq in AD • Source: Shutterstock

Making it two out of three, AbbVie Inc.'s Rinvoq met all key endpoints in its second Phase III Measure Up study, evaluating the JAK1 inhibitor’s potential as a once-daily oral treatment for atopic dermatitis.

AbbVie on 21 July said the compound, which was approved in the US and Europe in 2019 to treat certain...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Business

More from Scrip